Targets › GPX4
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Dec 2026.
Essential antioxidant peroxidase that directly reduces phospholipid hydroperoxide even if they are incorporated in membranes and lipoproteins. Can also reduce cholesterol hydroperoxide and thymine hydroperoxide (By similarity). (UniProt, P36969)
Open in Phaseline: the race on GPX4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sound Pharmaceuticals | Ebselen (SPI-1005) Glutathione peroxidase mimetic | GPX1, GPX2, GPX3, GPX4 | Phase 3 | Meniere's Disease; Hearing Loss | Dec 2026 |
Meniere's Disease (1) Hearing Loss (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.